计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| A123260-1g |
1g |
现货 ![]() |
| |
| A123260-5g |
5g |
现货 ![]() |
| |
| A123260-10g |
10g |
现货 ![]() |
| |
| A123260-25g |
25g |
现货 ![]() |
| |
| A123260-100g |
100g |
现货 ![]() |
|
| 别名 | 阿洛地平 | 6-甲基-2-(2-氨基乙氧基)甲基-4-(2-氯苯基)-1,4-二氢-3,5-吡啶二甲酸甲乙酯 |
|---|---|
| 英文别名 | 88150-42-9 (free base) | 3-Ethyl-5-methyl (+-)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate | AMLODIPINE (MART.) | BDBM50088383 | NCGC00165957-02 | Norvasc (TN) | 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-3-e |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Amlodipine |
| 生化机理 | 强效的长效L型钙通道阻滞剂(IC 50 = 1.9 nM)。还刺激一氧化氮合酶(NOS),降低血压并具有抗氧化特性。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 门控抑制剂 |
| 作用机制 | Ca v1.2的门控抑制剂;Ca v1.3的门控抑制剂;P2X4的异位调节剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
二氢吡啶类钙通道阻滞剂;主要活性作用的是( - ) - 异构体。 A dihydropyridine calcium channel blocker; activity resides mainly in the (-)-isomer. |
| 纯度 | ≥98% |
| PubChem SID | 488179669 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate |
| INCHI | 1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3 |
| InChi Key | HTIQEAQVCYTUBX-UHFFFAOYSA-N |
| Smiles | CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN |
| Isomeric SMILES | CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN |
| 分子量 | 408.88 |
| Reaxy-Rn | 3570229 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=3570229&ln= |
| 溶解性 | Soluble in dimethyl sulfoxide, ethanol, water, dimethyl formamide, acetone, chloroform, ethyl acetate and methanol.Water solubility:75.3 mg/L |
|---|---|
| 熔点 | 178-179 ºC |
| 分子量 | 408.900 g/mol |
| XLogP3 | 3.000 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 7 |
| 可旋转键计数Rotatable Bond Count | 10 |
| 精确质量Exact Mass | 408.145 Da |
| 单同位素质量Monoisotopic Mass | 408.145 Da |
| 拓扑极表面积Topological Polar Surface Area | 99.900 Ų |
| 重原子数Heavy Atom Count | 28 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 647.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 1 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS05, GHS06, GHS08, GHS09 |
|---|---|
| 信号词 | 危险 |
| 危险声明 |
H301: 吞咽会中毒 H318: 造成严重的眼睛损伤 H373: 通过长时间或反复暴露对器官造成损害 H400: 对水生生物有剧毒 H410: 对水生生物有剧毒并具有长期持续影响 |
| 预防措施声明 |
P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。 P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P273: 避免释放到环境中。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P321: 特殊处理(请参阅此标签上的...)。 P330: 漱口 P391: 收集溢出物 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P264+P265: 处理后彻底洗手[和…]。不要触摸眼睛。 P301+P316: 如果吞咽:立即寻求紧急医疗救助。 P305+P354+P338: 如果进入眼睛:立即用水冲洗几分钟。取下隐形眼镜(如果有的话),并且操作简单。继续冲洗。 P317: 寻求紧急医疗救助。 P319: 如果你感到不适,请寻求医疗帮助。 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | A123260 | |
| 分析证书 | A123260 | |
| 分析证书 | A123260 | |
| 分析证书 | A123260 | |
| 分析证书 | A123260 | |
| 分析证书 | A123260 | |
| 分析证书 | A123260 | |
| 分析证书 | A123260 | |
| 分析证书 | A123260 | |
| 分析证书 | A123260 | |
| 分析证书 | A123260 | |
| 分析证书 | A123260 | |
| 分析证书 | A123260 |
| 1. Christopoulos A, Changeux JP, Catterall WA, Fabbro D, Burris TP, Cidlowski JA, Olsen RW, Peters JA, Neubig RR, Pin JP et al.. (2014) International union of basic and clinical pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands.. Pharmacol Rev, 66 (4): (918-47). [PMID:25026896] |
| 2. Chehao Lee, Guang Xin, Fan Li, Chengyu Wan, Xiuxian Yu, Lijuan Feng, Ao Wen, Yu Cao, Wen Huang. (2023) Calcium/P53/Ninjurin 1 Signaling Mediates Plasma Membrane Rupture of Acinar Cells in Severe Acute Pancreatitis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24 (14): (11554). [PMID:37511311] [10.3390/ijms241411554] |
| 3. Ruike Song, Yanxia Li, Yiting Chen, Zhenli Qiu, Lu Huang. (2023) Chiral covalent organic framework incorporated organic polymer monolithic capillary column for enantioseparations. JOURNAL OF SEPARATION SCIENCE, 46 (8): (2201039). [PMID:36750206] [10.1002/jssc.202201039] |
| 4. Zhimin Gong, Gaobo Wang, Shuai Shao, Mengjie Wang, Kun Lu, Shixiang Gao. (2022) Co-degradation of coexisting pollutants methylparaben (mediators) and amlodipine in enzyme-mediator systems: Insight into the mediating mechanism. JOURNAL OF HAZARDOUS MATERIALS, 423 (127112). [PMID:34523479] [10.1016/j.jhazmat.2021.127112] |
| 5. Zhu-Jun Zhong, Zhong-Ping Yao, Zi-Qi Shi, Yang-Dan Liu, Li-Fang Liu, Gui-Zhong Xin. (2021) Measurement of Intracellular Nitric Oxide with a Quantitative Mass Spectrometry Probe Approach. ANALYTICAL CHEMISTRY, 93 (24): (8536–8543). [PMID:34107211] [10.1021/acs.analchem.1c01259] |
| 6. Yujie Zhang, Hui Zhong, Shouyong Zhou, Haifeng Han, Mingliang Zhang, Hongdeng Qiu. (2021) A docosyl-terminated polyamine amphiphile-bonded stationary phase for multimodal separations in liquid chromatography. JOURNAL OF CHROMATOGRAPHY A, 1642 (462045). [PMID:33735643] [10.1016/j.chroma.2021.462045] |
| 7. Lelin Zeng, Qin Yi, Qian Liu, Kewen Tang, Bart Van der Bruggen. (2021) Development of a new method and device for chiral drug enrichment and enantioseparation: Multiple-phase extraction and in situ coupling of crystallization. SEPARATION AND PURIFICATION TECHNOLOGY, 257 (117884). [10.1016/j.seppur.2020.117884] |
| 8. Lelin Zeng, Qian Liu, Bart Van der Bruggen, Kewen Tang, Xiang Yi, Guoxiang Wang. (2020) An integrated separation process for recovery and enantioseparation of amlodipine from wastewater: Supported liquid membrane-aqueous/organic phase crystallization. SEPARATION AND PURIFICATION TECHNOLOGY, 248 (117121). [10.1016/j.seppur.2020.117121] |
| 9. Shuai Shao, Li Qian, Xin Zhan, Mengjie Wang, Kun Lu, Jianbiao Peng, Dong Miao, Shixiang Gao. (2020) Transformation and toxicity evolution of amlodipine mediated by cobalt ferrite activated peroxymonosulfate: Effect of oxidant concentration. CHEMICAL ENGINEERING JOURNAL, 382 (123005). [10.1016/j.cej.2019.123005] |